Shots: Caribou to receive $40M up front in cash & equity investment, ~$300M in development, regulatory, and launch milestones along with additional commercial milestones and global royalties AbbVie will utilize […]readmore
Tags : License
Shots: Imcyse to receive up front, ~$180M as milestones along with royalties. Pfizer to purchase an equity stake in Imcyse Initially, the companies will collaborate to develop existing lead candidates […]readmore
Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will […]readmore
Shots: Asahi Kasei to receive an $20M up front, ~$210M as development & regulatory milestones and will be eligible for ~$180M milestones along with royalties on sales of the therapy. […]readmore
Shots: Artiva to receive $30M up front for the first 2 programs & an additional $15M, if Merck exercises its option for a third program. Artiva to get ~$612M/ program […]readmore
Shots: ImaginAb to receive license fees and other contingent payments and will partner with Neuvogen to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents in their clinical trials of […]readmore
Shots: Shionogi to receive an up front, milestones as well as royalties on sales of the therapy. BioAge to get exclusive US and EU rights to develop and commercialize BGE-17 […]readmore
Shots: ImaginAb to receive license fees and payments for manufacturing and other support and will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology […]readmore
Shots: Atara to receive $60M upfront and ~$610M as development, regulatory & commercialization milestones + tiered royalties on net sales. The collaboration focuses on off-the-shelf T-cell immunotherapy ATA3271 and ATA2271 […]readmore
Shots: Henlius to receive upfront, regulatory, and commercial milestone payments of ~$43M, eligible to receive $30M for every $1B above the first $600M of the cumulative net sales along with […]readmore